Superworth

Anixa Biosciences revenue ANIX

Sales by quarter and over the last twelve months, from 2010.

Last 12 months, to Oct 31, 2023
n/m
a quarter missing
Latest quarter, Q4 FY23
$0
Fiscal year 2023
n/a

Anixa Biosciences' twelve-month revenue can't be added up yet: a quarter of its results is missing from our data.

In its latest quarter, Q4 FY23, it was $0.

Revenue over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearRevenueChange
FY2023n/an/a
FY2021$512.5Kn/a
FY2019n/an/a
FY2018n/an/a
FY2017n/an/a
FY2016n/an/a
FY2015$9.3Mn/a
FY2014n/an/a
FY2013$388.9K−59%
FY2012$947.1K−6%
FY2011$1Mn/a
FY2010n/an/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedRevenueOn a year earlierLast 12 months
Q4 FY23$0n/an/a
Q3 FY23$0n/an/a
Q2 FY23$210Kn/an/a
Q4 FY21$0n/a$512.5K
Q3 FY21$0n/an/a
Q2 FY21$0n/an/a
Q1 FY21$512.5Kn/an/a
Q4 FY19$0n/an/a
Q3 FY19$0−100%n/a
Q2 FY19$250K−67%n/a
Q4 FY18$0n/an/a
Q3 FY18$362.5K+0%n/a

Against its peers

Companies in Drug Manufacturers - General nearest Anixa Biosciences' size, closest first, today.

CompanyRevenue, 12 monthsGrowth
ANIXAnixa Biosciencesn/m
LFVNLifevantage$182.6M−20% a year
SPROSpero Therapeutics$47M−3% a year
NATRNatures Sunshine Products$492M+7% a year
ATNMActinium Pharmaceuticalsn/m
ARVNArvinas$316.7M−15% a year
PBYIPuma Biotechnology$231.2M−3% a year
IRWDIronwood Pharmaceuticals$389.3M+26% a year
ZVRAZevra Therapeutics$136.1M+119% a year
CRMDCorMedix$462.2M+281% a year
COLLCollegium Pharmaceutical$808.2M+14% a year
Peer median$316.7M

What the revenue tells you

Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.

Growing revenue with shrinking margins is a warning, not a win.

More on Anixa Biosciences

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.